Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

243.45 -1.10 (-0.45%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

What the Options Market Tells Us About Johnson & Johnson ↗

March 03, 2025

Via Benzinga

Warren Buffett's State of the Market ↗

March 03, 2025

Berkshire's cash hoard is approaching "Dr. Evil" levels.

Via The Motley Fool

These Vanguard ETFs Show Where the Smart Money Is Moving Now ↗

March 03, 2025

Via The Motley Fool

Topics ETFs

3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income ↗

March 02, 2025

Via The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Right Now ↗

March 01, 2025

Via The Motley Fool

A Closer Look at Johnson & Johnson's Options Market Dynamics ↗

February 26, 2025

Via Benzinga

P/E Ratio Insights for Johnson & Johnson ↗

February 12, 2025

Via Benzinga

What's a Fair Price to Buy Johnson & Johnson Stock? ↗

February 12, 2025

Via The Motley Fool

Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform ↗

February 28, 2025

Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.

Via Benzinga

Topics ETFs Stocks

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang ↗

February 28, 2025

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Via Benzinga

Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company ↗

February 28, 2025

This virtually unknown company has been paying a continuous dividend for six decades longer than any other U.S. stock.

Via The Motley Fool

2 Stocks to Buy if There Is a Market Crash in 2025 ↗

February 09, 2025

Via The Motley Fool

(JNJ) - Analyzing Johnson & Johnson's Short Interest ↗

February 06, 2025

Via Benzinga

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says ↗

February 27, 2025

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Via Benzinga

Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug ↗

February 26, 2025

Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition.

Via Benzinga

Topics Lawsuit

3 Dividend-Paying Stocks Bucking the Market’s Trend

February 25, 2025

Via MarketBeat

Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market ↗

February 24, 2025

Many analysts are feeling better about the prospects for healthcare stocks in 2025.

Via Talk Markets

Topics ETFs Stocks / Equities

2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream ↗

February 24, 2025

Via The Motley Fool

Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income ↗

February 21, 2025

Via The Motley Fool

NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision ↗

February 20, 2025

NVIDIA (NASDAQ: NVDA) has introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research.

Via Benzinga

Topics Artificial Intelligence

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Topics ETFs Government World Trade

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗

February 18, 2025

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

Via Benzinga

Topics Government

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗

February 13, 2025

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Via Benzinga

Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead ↗

February 12, 2025

Josh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock.

Via Benzinga

Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates ↗

February 12, 2025

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ongoing efforts to refine its medtech division.

Via Benzinga

Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself' ↗

February 09, 2025

Via Benzinga

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

February 08, 2025

Via The Motley Fool

Topics Stocks

Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years ↗

February 07, 2025

On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Via Benzinga

Kenvue's Q4 Sales Miss, Margins Improve ↗

February 06, 2025

Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

Headline News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today